Physician profile
Christopher Lyons
NPI 1902808702
$11,092.43
in general payments reported to CMS, 2019-2025
37 companies · $2,259 in 2025
The $2,259 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $559 · 2021: $1,342 · 2022: $1,459 · 2023: $2,196 · 2024: $2,146 · 2025: $2,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,600.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,964.36 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,306.12 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,102.98 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $975.61 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $649.21 | 2022-2025 | |
| Qol Medical, LLC | $576.24 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $432.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $329.95 | 2019-2024 | Dificid |
| Ardelyx, INC. | $290.09 | 2022-2025 | Ibsrela |
| Celgene Corporation | $213.54 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $155.54 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $115.99 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $100.88 | 2021-2023 | |
| Lilly USA, LLC | $96.45 | 2023-2025 | Omvoh |
| Braintree Laboratories, INC. | $78.51 | 2019-2025 | Sutab, Suflave |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $73.46 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $73.30 | 2021-2024 | Rebyota |
| Pharmacosmos Therapeutics INC. | $70.03 | 2021-2022 | |
| Novo Nordisk INC | $63.12 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $52.39 | 2023 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $35.26 | 2025 | Terlivaz |
| Organon LLC | $33.85 | 2023-2025 | Hadlima, Renflexis |
| Boston Scientific Corporation | $30.06 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $26.99 | 2025 | Iqirvo |
| Amgen INC. | $26.42 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.82 | 2022 | |
| Daiichi Sankyo INC. | $24.66 | 2024 | Injectafer |
| Evoke Pharma, INC. | $23.08 | 2021 | |
| Shire North American Group INC | $22.67 | 2019 | |
| Ucb, INC. | $20.59 | 2019 | |
| Madrigal Pharmaceuticals | $18.53 | 2025 | Rezdiffra |
| Vivus LLC | $16.99 | 2024 | Qsymia |
| Allergan, INC. | $15.53 | 2020 | |
| Alfasigma USA, INC. | $14.58 | 2020 | |
| Concordia Pharmaceuticals INC. | $13.57 | 2019 | |
| Fresenius Kabi USA, LLC | $12.79 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.